(100 ml of Albumin 25%)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypotension During Dialysis
Conditions
Hypotension During Dialysis, Fluid Overload
Trial Timeline
Jun 3, 2015 → Dec 31, 2019
NCT ID
NCT04522635About (100 ml of Albumin 25%)
(100 ml of Albumin 25%) is a approved stage product being developed by Grifols for Hypotension During Dialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT04522635. Target conditions include Hypotension During Dialysis, Fluid Overload.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04522635 | Approved | Completed |
Competing Products
10 competing products in Hypotension During Dialysis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| REGN7544 + PB | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Droxidopa 100 MG [Northera] | Lundbeck | Approved | 82 |
| Droxidopa capsules + Placebo capsules | Lundbeck | Approved | 82 |
| Icatibant + Placebo | Pharvaris | Phase 3 | 72 |
| Ampreloxetine + Placebo | Theravance Biopharma | Phase 3 | 72 |
| ampreloxetine + Placebo | Theravance Biopharma | Phase 3 | 72 |
| ampreloxetine + Placebo | Theravance Biopharma | Phase 3 | 72 |
| TD-9855 + Placebo | Theravance Biopharma | Phase 2 | 47 |
| ampreloxetine | Theravance Biopharma | Phase 3 | 72 |
| Placebo + Fipamezole | Santhera Pharmaceuticals | Phase 2 | 44 |